The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with ...

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Shares of Novo Nordisk (NVO) are rising early Monday after the US Food and Drug Administration approved Wegovy to treat ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) ...

Novo Nordisk shares were climbing Monday after the Food and Drug Administration approved the popular weight-loss drug Wegovy ...